Skip to main content
Premium Trial:

Request an Annual Quote

Ruedi Aebersold, Katia Sol-Church

Ruedi Aebersold was awarded the ABRF Award this week at the Association of Biomolecular Resource Facilities’ annual conference. The award recognizes contributions by an individual to biomolecular technologies and applications. He is a co-founder of the Institute for Systems Biology and a full faculty member. He is also a professor of molecular systems biology at the Federal Technical University in Zurich and the University of Zurich.

Katia Sol-Church was awarded the first ABRF Outstanding Research Group/Committee Member of the Year. The award is presented to a member of a Research Group or Committee who ABRF’s executive board feels “represents the best qualities of our members in terms of their service, expertise, and dedication” to the association. Sol-Church is lab director at the Al duPont Hospital for Children in Wilmington, Del.
She currently is on the Nucleic Acids Research Group and was previously on the Fragment analysis Research Group where she served as chair. She also was chair of the DSRG/FARG/NSRG join research project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.